Differences in exhaled nitric oxide in atopic children

Background: Exhaled nitric oxide (FeNO) has been introduced in the diagnosis and control of asthma. Atopy related diseases are a common comorbidity in asthma, but in these cases the FeNO values and their relevance have not been clearly defined. In this study we compared the differences in FeNO levels invarious atopic conditions. Methods: A prospective study was performed comparing online FeNO in six groups of patients (non-atopic control, asymptomatic atopic, non-active rhinitis, active rhinitis, asthma, asthma with rhinitis). Results: 90 children (15 per group) assisted in an out patient hospital clinic were enrolled. FeNO levels (ppb) were: 7.9 (non-atopic control), 19 (asymptomatic atopic), 16.6 (non-active rhinitis), 26.3 (active rhinitis), 31 (asthma), and 35 (asthma and rhinitis). All groups presented higher levels of FeNO than the non-atopic control group (P < 0.001). Both asthma groups had higher levels than the rest of the groups (P < 0.05), except for the active rhinitis group. Dispersion of FeNO levels was wide in the study sample. No correlation was found between FeNO and FEV1. A weak correlation was seen with age (r = 0.28) Conclusions: Atopy, rhinitis and its exacerbations can be confounders in the interpretation of FeNO levels in asthmatic children

No disponible

Tolerance of a Salsola kali extract standardized in biological units administered by subcutaneous route. Multicenter study

Background: Sensitivity to Salsola kali is a frequent cause of allergic respiratory disease in various regions of Spain. However, there are very few articles in which this allergen has been studied. Methods and Results: In order to evaluate the tolerance of this extract, a prospective study has been performed. This study was observational, multi-centred and open, involving 88 patients with allergic respiratory disease due to sensitivity to Salsola, aged between 5 and 52 years. The administration of the extract was performed subcutaneously, through one of two treatment schedules: cluster (8 doses in 4 visits) or conventional (13 doses in 12 visits). A total of 42 adverse reactions were registered, in 26 patients (35 local reactions in 21 patients and 7 systemic reactions in 6 patients). Among the 7 systemic reactions, 4 were registered with the cluster protocol and 2 with the conventional protocol (p = 0.329). In no patients were serious adverse reactions registered. Conclusion: The subcutaneous administration of a Salsola extract is safe and well tolerated, both when administered using a conventional schedule and when using a cluster schedule

Antecedentes: La sensibilización a Salsola kali es una causa frecuente de enfermedad alérgica respiratoria en varias zonas de España. Sin embargo, apenas existen publicaciones en las que se estudie este alergeno. Métodos y resultados: Para valorar la tolerancia de este extracto, se ha realizado un estudio prospectivo, observacional, multicéntrico y abierto, en el que se han incluido 88 pacientes, de edad entre 5 y 52 años, con enfermedad alérgica respiratoria por sensibilización a Salsola. La administración del extracto se ha realizado por vía subcutánea, mediante dos esquemas de tratamiento: agrupada (8 dosis en 4 visitas) o convencional (13 dosis en 12 visitas). Se han registrado un total de 42 reacciones adversas en 26 pacientes (35 locales en 21 pacientes y 7 sistémicas en 6 pacientes). De las 7 reacciones sistémicas, 4 se registraron con la pauta agrupada y 2 con la convencional (p = 0,329). No se registró ninguna reacción adversa grave. Conclusión: La administración subcutánea de un extracto de Salsola es segura y bien tolerada, tanto cuando se administra con una pauta convencional como con una pauta agrupada